ArticleCureus2025
A Deadly Duet: Fanconi Anemia (FA) With Head and Neck Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Squamous Cell Carcinoma of the Skin in a Teenager with Fanconi Anemia: A Challenging Treatment.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fanconi anemia (FA) is a rare, inherited disorder characterized by chromosomal instability, bone marrow failure, and predisposition to malignancies, including head and neck squamous cell carcinoma (HNSCC). The treatment of HNSCC in FA is challenging due to the extreme sensitivity of these patients to DNA-damaging agents. A 39-year-old male with FA presented with odynophagia and neck swelling. Examination revealed a mass at the base of the tongue (BOT) with bilateral cervical lymphadenopathy. Histopathology confirmed moderately differentiated squamous cell carcinoma (MD-SCC) (p16 negative). He underwent induction chemotherapy but developed severe myelosuppression. In view of the unusual clinical presentation, a mitomycin stress test was performed, confirming FA. Consequently, further chemotherapy was deferred, and radiotherapy was delivered with careful monitoring and supportive care. The patient achieved a complete metabolic response post-treatment. The case highlights the importance of radiation treatment in FA patients with exaggerated chemotherapy toxicities and the need for tailored management in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.